Entrectinib

Major

Entrectinib Vorasidenib Voranigo Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Entrectinib Voriconazole Vfend An increased risk of QT interval prolongation, an increased entrectinib exposure, an increased entrectinib-related adverse effects... Details Entrectinib Vorinostat Zolinza An increased risk of QT interval prolongation Details Entrectinib Voxelotor Oxbryta Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Ziftomenib Komzifti An increased risk of QT interval prolongation and torsade de pointes Details Entrectinib Zotepine An increased risk of QT interval prolongation Details Entrectinib Zuclopenthixol An increased risk of QT interval prolongation Details Entrectinib Eribulin Injection Halaven An increased risk of QT interval prolongation Details Entrectinib Famotidine Injection Calmicid An increased risk of QT interval prolongation Details Entrectinib Foscarnet Injection Foscavir An increased risk of QT interval prolongation Details Entrectinib Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation Details Entrectinib Goserelin Implant Zoladex An increased risk of QT interval prolongation Details Entrectinib Granisetron Transdermal Patch Sancuso An increased risk of QT interval prolongation Details Entrectinib Granisetron Injection Granisol An increased risk of QT interval prolongation Details Entrectinib Histrelin Implant Supprelin An increased risk of QT interval prolongation Details Entrectinib Inotuzumab Ozogamicin Injection Besponsa An increased risk of QT interval prolongation Details Entrectinib Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Entrectinib Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Entrectinib Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Entrectinib Letermovir Injection Prevymis Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Levofloxacin Injection Levaquin An increased risk of QT interval prolongation Details Entrectinib Metronidazole Injection Flagyl An increased risk of QT interval prolongation Details Entrectinib Metronidazole Topical MetroCream® An increased risk of QT interval prolongation Details Entrectinib Metronidazole Vaginal MetroGel® Vaginal An increased risk of QT interval prolongation Details Entrectinib Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Entrectinib Moxifloxacin Injection Avelox An increased risk of QT interval prolongation Details Entrectinib Moxifloxacin Ophthalmic Moxeza® An increased risk of QT interval prolongation Details Entrectinib Nafarelin Nasal Spray Synarel An increased risk of QT interval prolongation Details Entrectinib Nafcillin Injection Unipen® Injection Reduced entrectinib exposure and reduced efficacy of entrectinib Details Entrectinib Octreotide Injection Bynfezia An increased risk of QT interval prolongation Details Entrectinib Ofloxacin Ophthalmic Ocuflox An increased risk of QT interval prolongation Details Entrectinib Ofloxacin Otic Floxin® Otic An increased risk of QT interval prolongation Details Entrectinib Olodaterol Oral Inhalation Striverdi An increased risk of QT interval prolongation and an increased risk of ventricular arrhythmias Details Entrectinib Oxaliplatin Injection Eloxatin® Increased risk of QT-interval prolongation Details

Moderate

Entrectinib Hydrocortisone Ala-Cort Increased hydrocortisone exposure and an increased risk of hydrocortisone-related adverse reactions Details Entrectinib Kratom Increased CYP3A substrate exposure Details Entrectinib Levothyroxine Ermeza Increased risk of hypothyroidism Details Entrectinib Mavacamten Camzyos Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Entrectinib Rilzabrutinib Wayrilz Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Entrectinib Tenofovir Alafenamide Increased tenofovir alafenamide exposure and an increased risk of tenofovir alafenamide-related adverse effects Details